ResApp Health Ltd (ASX: RAP) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

ResApp Health Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $69.59 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 859.20 million
Earnings per share -0.011
Dividend per share N/A
Year To Date Return -10.59%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

ResApp Health Ltd (ASX: RAP)
Latest News

RAP ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About ResApp Health Ltd

ResApp Health Ltd is engaged in development and commercialization of the ResApp technology for the purpose of providing health care solutions for respiratory disease. The company's solutions are designed to be easily integrated into existing telehealth solutions and it is working on apps to provide respiratory disease diagnosis and management directly to consumers and healthcare providers. Its products are for Acute Disease Diagnosis; for Chronic Disease Management; and for Sleep Apnoea.

RAP Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
17 Sep 2021 $0.08 $0.01 13.16% 1,660,822 $0.08 $0.08 $0.08
16 Sep 2021 $0.08 $0.00 0.00% 1,493,098 $0.08 $0.08 $0.08
15 Sep 2021 $0.08 $0.00 0.00% 11,775,308 $0.09 $0.09 $0.07
14 Sep 2021 $0.08 $-0.01 -11.24% 22,909,913 $0.09 $0.10 $0.08
13 Sep 2021 $0.09 $0.02 27.03% 17,810,997 $0.08 $0.09 $0.08
10 Sep 2021 $0.07 $0.02 34.48% 22,555,047 $0.06 $0.08 $0.06
09 Sep 2021 $0.06 $0.00 0.00% 1,717,971 $0.06 $0.06 $0.06
08 Sep 2021 $0.06 $0.00 0.00% 374,273 $0.06 $0.06 $0.06
07 Sep 2021 $0.06 $0.00 0.00% 1,413,959 $0.06 $0.06 $0.06
06 Sep 2021 $0.06 $0.01 18.87% 6,815,003 $0.05 $0.06 $0.05
03 Sep 2021 $0.05 $0.00 0.00% 3,846,001 $0.05 $0.06 $0.05
02 Sep 2021 $0.05 $0.00 0.00% 1,449,803 $0.05 $0.05 $0.05
01 Sep 2021 $0.05 $0.00 0.00% 527,230 $0.05 $0.05 $0.05
31 Aug 2021 $0.05 $0.00 0.00% 518,970 $0.05 $0.05 $0.05
30 Aug 2021 $0.05 $0.00 0.00% 1,237,365 $0.05 $0.05 $0.05
27 Aug 2021 $0.05 $0.00 0.00% 2,028,339 $0.05 $0.05 $0.05
26 Aug 2021 $0.05 $0.00 0.00% 600,744 $0.05 $0.05 $0.05
25 Aug 2021 $0.05 $0.00 0.00% 2,173,279 $0.05 $0.05 $0.05
24 Aug 2021 $0.05 $0.00 0.00% 782,849 $0.05 $0.05 $0.04
23 Aug 2021 $0.05 $0.00 0.00% 921,738 $0.04 $0.05 $0.04
20 Aug 2021 $0.04 $0.00 0.00% 1,082,130 $0.04 $0.05 $0.04
19 Aug 2021 $0.04 $0.00 0.00% 429,229 $0.04 $0.04 $0.04
18 Aug 2021 $0.05 $0.00 0.00% 1,190,316 $0.04 $0.05 $0.04

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
15 Mar 2021 Roger Aston Buy 290 $20,300
On-market trade.
15 Mar 2021 Christopher Ntoumenopoulos Buy 500 $35,500
On-market trade.
15 Mar 2021 Anthony (Tony) Keating Buy 225 $16,200
On-market trade.
02 Dec 2020 Michael Stein Issued 500 $45,000
Issue of options.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr Roger Aston Non-Executive ChairmanNon-Executive Director Jul 2015
Dr Aston is a scientist and seasoned biotechnology entrepreneur. He has been closely involved in start-up companies and major pharmaceutical companies. Aspects of his experience include US Food and Drug Administration (FDA) and European Union (EU) product registration, clinical trials, global licensing agreements, fundraising through private placements, and a network of contacts within the pharmaceutical, banking and stock broking sectors. Dr Aston has also held Directorships/Chairmanships with Clinuvel Ltd, HalcyGen Ltd, and Ascent Pharma Ltd, was a member of the AusIndustry Biological Committee advising the Industry Research and Development Board. He is hollding other directorship with Immuron Limited and Oncosil Medical Limited.
Dr Michael Stein Non-Executive Director Apr 2020
Dr Stein is currently acting CEO of immuno-oncology company, Valo Therapeutics. Immediately prior to Valo, Michael was the founding CEO of OxStem Ltd, an award-winning biotechnology spinout from the University of Oxford. Michael previously served as founding CEO for Doctor Care Anywhere, a UK-based telemedicine platform acquired by Synergix in 2015. In 2001, he cofounded the Map of Medicine with University College London and was founding CEO. The Map was a set of clinical algorithms that represented the patient healthcare journey from suspected diagnosis to treatment across all healthcare settings. The Map was nationally licensed across NHS England and was acquired by Hearst Business Media in 2008.
Mr Brian Willoughby Leedman Executive Director Corporate Affairs May 2021
Mr Leedman has over 15 years of experience in investor relations and with an understanding of healthcare investors' requirements. Mr Leedman has managed investor relations for the company (ResApp Health Limited) since its ASX listing in 2015, most recently as Vice President, Corporate Affairs. Between February 2016 and December 2017, Mr Leedman served on the board of directors as Executive Director, Corporate Affairs. Mr Leedman is currently Non-Executive Chairman of three ASX listed healthcare companies.
Mr Christopher Ntoumenopoulos Non-Executive Director Jan 2015
Mr Ntoumenopoulos is the Managing Director of Twenty 1 Corporate. He has worked in financial markets for the past 15 years, focusing on Capital Raisings, Portfolio Management and Corporate Advisory. Mr Ntoumenopoulos has advised and funded numerous ASX companies from early stage venture capital, through to IPO. He is an executive director of various private companies which span across finance, technology and medical sectors. Christopher is holding other directorship with Race Oncology Ltd.
Dr Anthony (Tony) Keating Chief Executive OfficerManaging Director Jul 2015
Dr Keating has over ten years' experience in commercialising technology. Dr Keating created the initial business strategy for ResApp and has led the commercialization of ResApp's technology to date. Previously, Dr Keating was Director, Commercial Engagement at UniQuest Pty Ltd. While at UniQuest, Dr Keating held roles as interim Chief Executive Officer and Non-Executive Director for a number of privately-held, venture-capital funded start-up companies. Prior to joining UniQuest Dr Keating held business development and engineering management roles at Exa Corporation, a US-based software company that was listed on the NASDAQ and later acquired by Dassault Systemes.
Ms Nicki Farley Company Secretary
-
Nicki Farley Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 69,891,549 9.26%
Freeman Road Pty Ltd 40,500,000 5.36%
J P Morgan Nominees Australia Pty Limited 17,600,530 2.33%
Bnp Paribas Nominees Pty Ltd 17,266,887 2.29%
Mr Frank Weng Thong Chew 13,168,000 1.74%
Mr Anthony James Keating 10,000,000 1.32%
Equimetrixs Pty Ltd 8,437,500 1.12%
Narhex Life Sciences Developments Pty Ltd 7,997,005 1.06%
Cem International (Asia) Pty Ltd 7,849,888 1.04%
Mr Yongsheng Peng & Mrs Yuezhen Xie 4,798,502 0.64%
Let Superannuation Pty Ltd 4,444,103 0.59%
Citicorp Nominees Pty Limited 4,436,079 0.59%
Mr Victor John Wilk 4,400,000 0.58%
Mr Trent Antony Goodrick 4,000,000 0.53%
Wilk Holdings Pty Ltd 4,000,000 0.53%
Queensland Forest Industries Pty Ltd 3,806,830 0.50%
Gardmac Pty Ltd 3,681,395 0.49%
Mr Jason Dennis Roberts 3,431,954 0.45%
Dr Geoffrey Waring 3,303,764 0.44%
Sobol Capital Pty Ltd 3,109,375 0.41%

Profile

since

Note